From probiotics to therapeutics: Another step forward?

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2149-2152

  Ghishan, Fayez K ^a   Kiela, Pawel R ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROBIOTIC AGENT; PROTEIN P40;

CELL PROTECTION; COLITIS; DRUG EFFICACY; HUMAN; LACTOBACILLUS RHAMNOSUS; NONHUMAN; NOTE; PRIORITY JOURNAL;

ANIMALS; BACTERIAL PROTEINS; COLITIS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FOOD MICROBIOLOGY; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS RHAMNOSUS; METAGENOME; MICE; MICROBIAL CONSORTIA; MICROBIAL INTERACTIONS; OPPORTUNISTIC INFECTIONS; PROBIOTICS; PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS;

EID: 79957880120     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58025     Document Type: Note

References (18)

1. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449(7164):804-810. (Pubitemid 47598620)
2. Goodacre R. Metabolomics of a superorganism. J Nutr. 2007;137(1 suppl):259S-266S.
3. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ. Microbiota restoration: nat ural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27-38.
4. Metchnikoff E. The Nature of Man: Studies in Optimistic Philosophy. New York, New York, USA: GP Putman's Sons; 1908.
5. Agheyisi R. The Probiotics Market: Ingredients, Supplements, Foods. BCC Research. Report #FOD035B. http://www.bccresearch.com/report/probiotic- supplements-food-fod035b.html. Updated June 2008. Accessed April 8, 2011.
6. Aureli P, et al. Probiotics and health: an evidencebased review [published online ahead of print February 22, 2011]. Pharmacol Res. doi:10.1016/j.phrs.2011.02.006.
7. Yan F, Polk DB. Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol. 2010;26(2):95-101.
8. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A. 2007;104(18):7617-7621. (Pubitemid 47185955)
9. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol. 2010;8(3):171-184.
10. O'Mahony C, et al. Commensal-induced regulatory T cells mediate protection against pathogenstimulated NF-kappaB activation. PLoS Pathog. 2008;4(8):e1000112.
11. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46(suppl 2):S96-S100. (Pubitemid 351323674)
12. Preidis GA, Hill C, Guerrant RL, Ramakrishna BS, Tannock GW, Versalovic J. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology. 2011;140(1):8-14.
13. Kruis W, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617-1623.
14. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10(11):PI126-PI131.
15. Yan F, Polk DB. Probiotic bacterium prevents cytokine- induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277(52):50959-50965. (Pubitemid 36042264)
16. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 2007;132(2):562-575. (Pubitemid 46274659)
17. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2008;294(4):G1060-G1069. (Pubitemid 351520059)
18. Yan F, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest. 2011;121(6):2242-2253.